PHBIPharmagreen Biotech Inc.

About Pharmagreen Biotech Inc. (PHBI)

Pharmagreen Biotech Inc. (PHBI) is a Drug Manufacturers - Specialty & Generic company headquartered in Coquitlam, BC, Canada whose shares trade over-the-counter on the Pink tier.

Pharmagreen Biotech Inc. (OTC Markets: PHBI) is developing its line of nutraceutical products, a proprietary blend of therapeutic plants and mushrooms. Pharmagreen's first new product, MaxGenomic(TM) Supplement, is a proprietary blend, formulated in the U. S. A., of nine medicinal mushrooms and six medicinal plants to help support the human mind and body. This supplement is produced in a U.S.A cGMP facility, in enteric capsules to enhance the bioavailability of the MaxGenomic(TM) supplement. Pharmagreen is also completing its research for its elixir, sublingual version, to provide immediate help and support to those who push their mental and physical capacity to their limits. Utilizing the Company's expertise in plant genetics, tissue culture, Pharmagreen's transgenic program uses the current technologies to research and create nutraceutical formulations as daily supplements, with the potential to improve lives and address a wide variety of aliments.

Products and services

A formulator of nutraceutical products, a proprietary blend of therapeutic plants and mushrooms. Pharmagreen's first new product, MaxGenomic(TM) Supplement, is a proprietary blend, formulated in the U. S. A., of nine medicinal mushrooms and six medicinal plants to help support the human mind and body. This supplement is produced in a U.S.A. cGMP facility, in enteric capsules to enhance the bioavailability of the MaxGenomic(TM) supplement. Consulting services for Cannabis industry for those seeking to maximize their yields utilizing Pharmagreen's proprietary cultivation and processing technologies.

PHBI key facts

Ticker symbol

PHBI

Market tier

Pink

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Coquitlam, BC, Canada

Country of incorporation

US

Year of incorporation

2007

Employees

3

Estimated market cap

$862.7K (as of Apr 10, 2025)

Shares outstanding

663,645,739

Reporting standard

Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

9/30

Latest filing

Quarterly Report (Dec 31, 2024)

Pharmagreen Biotech Inc. leadership

• Peter Wojcik — CEO
• Ronald S McIntyre — Consultant
• Terry Kwan — Principal Acct. Officer

Explore more: Drug Manufacturers - Specialty & Generic stocks · Healthcare sector · Pink stocks · OTC stocks starting with P